Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

Launched by CAREVIVE SYSTEMS, INC. · Aug 2, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on understanding the experiences of patients with breast cancer, lung cancer, ovarian cancer, multiple myeloma, or acute myelogenous leukemia while they are receiving treatment. The researchers want to gather real-world data about how these patients are feeling by using a special electronic system that allows them to report their symptoms from home or any location they choose. Patients will start by completing a survey about their health, and then they will answer weekly surveys for at least 12 weeks to provide ongoing feedback about their symptoms and treatment experience.

To participate, you need to be at least 18 years old and have one of the specified types of cancer, regardless of your treatment stage. It's important that you can complete online surveys using a mobile device or computer and understand English. If you join the study, you can expect to share your experiences regularly, which will help researchers improve care for future patients. This trial is currently recruiting participants, so if you meet the criteria, you could play a vital role in helping advance cancer treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All participants must be 18 years of age or older.
• • Subjects may be any stage and anywhere in the treatment continuum.
• • Subject participants must have a diagnosis of a breast, lung, AML, ovarian cancer or multiple myeloma.
• • Subjects must be able to complete on-line surveys using a cell phone, tablet, or computer.
• • All participants must be able to understand English.
• Exclusion Criteria:
• • Any patient who cannot understand written or spoken English.
• • Any patient without the ability to complete on-line surveys using a cell phone, tablet, or computer.
• • Any patient on a treatment clinical trial.
• • Any prisoner and/or other vulnerable persons as defined by NIH (45 CFR 46, Subpart B, C and D).